Portage Biotech Inc. (PRTG)
8.45
-0.82 (-8.85%)
At close: Apr 25, 2025, 1:07 PM
-8.85% (1D)
| Bid | 8.39 |
| Market Cap | 9.47M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -67.28M |
| EPS (ttm) | -68.17 |
| PE Ratio (ttm) | -0.12 |
| Forward PE | -0.87 |
| Analyst | n/a |
| Ask | 8.63 |
| Volume | 70,086 |
| Avg. Volume (20D) | 1,234,879 |
| Open | 9.15 |
| Previous Close | 9.27 |
| Day's Range | 8.26 - 9.29 |
| 52-Week Range | 2.10 - 23.01 |
| Beta | 0.97 |
About PRTG
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable pep...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 2, 2002
Employees 7
Stock Exchange NASDAQ
Ticker Symbol PRTG
Website https://www.portagebiotech.com
4 weeks ago
+103.82%
Portage Biotech shares are trading higher after th...
Unlock content with
Pro Subscription
4 weeks ago
+3.74%
Portage Biotech shares are trading higher after the company reported new data for PORT-7 at the 2025 European Lung Cancer Congress.
